More than 500,000 Australians with a potentially fatal heart rhythm disorder can now be treated by new technology which could ...

Management stated that these milestones further validate the potential benefits of nsPFA and increase awareness of the ...

Shares of Veradermics Inc. spiked as the first top-line readout from its registrational program for VDPHL-01 showed the oral, extended-release version of minoxidil surpassed expectations in men with ...

Earnings call Johnson & Johnson delivered Q1 2026 operational sales growth of 6.4% (7.4% in Innovative Medicine, 4.6% in MedTech), beating consensus and raising full-year guidance. Excluding STELARA, ...

Could tickling your ears with electricity really boost your V02 max? Simon Fellows investigates the strange but promising potential of vagus nerve stimulation ...

AVANT GUARD trial meets expectations despite pause for safety modifications ...

We conducted an international, randomized trial involving patients with previously untreated persistent atrial fibrillation. The patients were randomly assigned in a 2:1 ratio to receive PFA performed ...

Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...

Medical device suppliers that produce parts and components for pulsed field ablation (PFA) catheters designed to treat atrial fibrillation (AFib) are optimistic about growth since Medtronic’s ...

A new clinical trial found that pulsed-field catheter ablation using Boston Scientific's Farapulse system was more effective than medication in treating persistent atrial fibrillation. One year after ...

A novel pulsed field ablation technology was safe and prevented atrial arrhythmia recurrence in most patients with paroxysmal ...

There are both clinical and economic implications, as payers have been discouraging ablation in this population, one expert ...